Ruiqi Zhao

Dr. Ruiqi Zhao


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2026 in Life
Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
MHMengyao Han
Mengyao Han
BZBei Zhang
Bei Zhang
MMMengqing Ma
Mengqing Ma
KFKongli Fan
Kongli Fan
XZxiaozhou zhou
xiaozhou zhou
Primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) exhibit a striking clinical comorbidity, with 60–80% of PSC patients concurrently harboring UC, yet the shared immunogenetic mechanisms remain poorly understood. Here, we constructed a multi-omics integrative framework to systematically dissect the cellular and molecular basis of this comorbidity. GWAS meta-analyses were performed for each disease, followed by tissue-level enrichment assessment using QTLEnrich, MAGMA, and gsMap spatial mapping. Single-cell transcriptomic atlases were constructed, and cell-type prioritization was conducted using four complementary methods. Core genes were identified through cross-validation of five algorithms, with subsequent genomic fine-mapping via FUMA and GCTA-COJO. Tissue-level analyses consistently identified the intestine and immune-related tissues as commonly affected. Multi-dimensional evidence integration prioritized natural killer (NK) cells as the core effector cell type for both diseases, supported principally by CELLECT (Cell-type Expression-specific Integration for Complex Traits) heritability enrichment and single-cell differential analysis. Convergence of five gene-level algorithms pinpointed STAT3 as the sole high-confidence comorbidity gene, broadly expressed across immune cell populations and exhibiting tissue-differential alternative splicing. Colocalization identified a high-risk variant (rs3736161) within the STAT3 locus, with conditional analysis revealing 35 additional independent signals. These findings identify the NK cell–STAT3 axis as a central immunogenetic hub connecting PSC and UC, offering potential therapeutic targets for comorbidity management.

28 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
BZBei Zhang
Bei Zhang
MHMengyao Han
Mengyao Han
MLMinling Lv
Minling Lv
JSJialing Sun
Jialing Sun
XZxiaozhou zhou
xiaozhou zhou
Background/Objective: Histone deacetylase inhibitors (HDACi) represent a novel class of antineoplastic agents, yet their comprehensive safety profile warrants further investigation. This study aimed to examine the safety of HDACi using the FDA Adverse Event Reporting System (FAERS) and to explore causal relationships through Mendelian randomization (MR) analysis of drug targets. Methods: Adverse drug event (ADE) reports for Vorinostat, Romidepsin, Belinostat, and Panobinostat submitted to the FAERS from their respective market entry dates through 31 December 2023, were analyzed using disproportionality analyses with four algorithms, supplemented by time-to-onset analysis, logistic regression, and MR analysis. Results: A total of 1360, 1065, 225, and 1234 ADE reports were documented for Vorinostat, Romidepsin, Belinostat, and Panobinostat, respectively. Eight preferred terms, including decreased white blood cell, platelet, and neutrophil counts, hypophosphatemia, hypocalcemia, QT prolongation, increased aspartate aminotransferase, and anemia, exhibited positive signals across all four HDACi. A temporal decline in the risk of most HDACi-related ADEs was observed, and age, gender, and weight were identified as potential confounding factors for important medical events. Notably, MR analysis revealed a positive correlation between HDAC5 expression and serum phosphate levels. Conclusions: This pharmacovigilance study provides hypothesis-generating evidence that hypophosphatemia may represent a potential class effect of HDACi.

14 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
STShiqi Tang
Shiqi Tang
MHMengyao Han
Mengyao Han
HHHui Hu
Hui Hu
JGJiesheng Guo
Jiesheng Guo
XZxiaozhou zhou
xiaozhou zhou
Background/Objectives: Chemotherapy-induced nausea and vomiting (CINV) is common and compromises quality of life and adherence. 5-HT3 receptor antagonists (RAs) and NK-1 RAs are cornerstones, yet adverse event patterns associated with their concomitant use are not well characterized. Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 Q1–2025 Q1 and deduplicated reports per Food and Drug Administration (FDA) guidance. Five algorithms—the Ω shrinkage measure, additive model, multiplicative model, combination risk ratio, and chi-square model—detected disproportionate reporting signals associated with concomitant use. We also performed time-to-onset (TTO) analysis and logistic regression. Results: We identified 965 concurrent use cases with a mean age of 58 years and a mean weight of 70 kg, with 59.7% (n = 575) of these cases being female. These reports included 366 preferred terms (PTs). Forty-nine PTs were significant across all five algorithms, mainly skin and subcutaneous disorders, hypersensitivity reactions, blood pressure abnormalities, hepatic and renal impairment, and nervous system disorders, with additional signals for abnormal antidiuretic hormone secretion, respiratory disorders, and oropharyngeal disorders. TTO showed most adverse drug events (ADEs) occurred within 20 days of therapy initiation. Logistic regression indicated that older age was associated with higher odds of classification as an important medical event (IME). Conclusions: Beyond prescribing information, we detected previously unrecognized adverse event terms that were disproportionately reported with concomitant use and that merit attention in practice.

7 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
MHMengyao Han
Mengyao Han
BZBei Zhang
Bei Zhang
MMMengqing Ma
Mengqing Ma
XZxiaozhou zhou
xiaozhou zhou
JSJialing Sun
Jialing Sun
Background/Objectives: Immune evasion remains a critical barrier to effective hepatocellular carcinoma (HCC) therapy. Lactate dehydrogenase A (LDHA) drives lactate accumulation and histone lysine lactylation (Kla), reshaping the immunosuppressive microenvironment, while bromodomain-containing protein 4 (BRD4) sustains B7-H3 transcription via super-enhancer occupancy. Despite their synergistic roles in the lactate–Kla–B7-H3 immunosuppressive axis, no dual-target inhibitor simultaneously engaging both proteins has been reported. This study aimed to discover dual LDHA/BRD4 inhibitors from natural product libraries using an integrated AI-driven computational pipeline. Methods: We established a multi-tier virtual screening cascade comprising Lipinski/QED drug-likeness filtration, DiffDock-based AI docking, QuickVina binding energy validation, PLIP interaction profiling, 200 ns all-atom molecular dynamics simulations, MM-GBSA binding free energy calculations, and density functional theory analysis. Natural product libraries from COCONUT and CMNPD databases (84,730 compounds post-filtration) were screened against both targets. Results: High-throughput DiffDock screening identified 11 dual-target hits, from which CNP0038114.1 and CMNPD16582 emerged as prioritized lead candidates. All four protein–ligand complexes maintained structural stability throughout MD simulations, with MM-GBSA binding free energies ranging from −27.24 to −32.45 kcal/mol, predominantly driven by van der Waals interactions. DFT calculations revealed distinct electronic profiles: CNP0038114.1 exhibited a narrow HOMO–LUMO gap (2.718 eV) favoring charge-transfer reactivity, whereas CMNPD16582 displayed a larger gap (4.822 eV), suggesting superior chemical stability. Conclusions: This computational study furnishes two novel natural product leads for targeting the lactate–Kla–B7-H3 immunosuppressive axis in HCC, establishing a generalizable AI-driven workflow for dual-target inhibitor discovery.

Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
JGJiesheng Guo
Jiesheng Guo
MHMengyao Han
Mengyao Han
STShiqi Tang
Shiqi Tang
HHHui Hu
Hui Hu
XZxiaozhou zhou
xiaozhou zhou
The co-occurrence of liver cirrhosis (LC) and heart failure (HF) poses considerable clinical challenges, yet the cellular and molecular determinants of this comorbidity remain poorly characterized. To address this, we developed an integrative multi-omics pipeline encompassing GWAS meta-analysis, gsMap-based spatial transcriptomic projection, GeneEnrich functional annotation, single-cell atlas construction, seismicGWAS and ECLIPSER cell-type scoring, eCAVIAR and fastenloc colocalization, hdWGCNA network inference, scTenifoldKnk in silico gene perturbation, and GCTA-COJO fine-mapping. Quality-controlled meta-analysis yielded 12,347,758 and 9,256,862 variant-level associations for LC and HF, respectively. Spatial projection confirmed preferential enrichment of disease signals within embryonic hepatic and cardiac compartments. Pathway analyses disclosed that LC-linked loci were concentrated in lipid metabolic programs, whereas HF-linked loci implicated mitochondrial bioenergetics and lysosomal degradation. At the cellular level, endothelial cells emerged as the dominant HF-associated population. Convergent evidence from five orthogonal algorithms pinpointed CRIM1 as the sole robustly supported shared gene, selectively enriched in HF endothelial cells; virtual perturbation further identified LCP1 and PTPRC as downstream regulatory nodes. Fine-mapping of the chromosome 2 locus harboring rs12476437 revealed multiple statistically independent signals in the vicinity of CRIM1. Collectively, these findings computationally prioritize the endothelial–CRIM1 axis as a previously unappreciated candidate mechanistic bridge between LC and HF requiring experimental validation.

Verified
Journal Article
Open access
PDF file
RZRuiqi Zhao
Ruiqi Zhao
JYJiahua Yang
Jiahua Yang
MHMengyao Han
Mengyao Han
STShiqi Tang
Shiqi Tang
HHHui Hu
Hui Hu
XZxiaozhou zhou
xiaozhou zhou
Apoptosis signal-regulating kinase 1 (ASK1) represents a critical therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Natural products, owing to their unique chemical diversity, constitute a rich reservoir for discovering novel ASK1 inhibitors. The emergence of artificial intelligence-assisted drug discovery (AIDD) has opened new avenues for exploring small-molecule inhibitors. Through virtual screening, molecular docking, interaction profiling, molecular dynamics simulations, and MM-GBSA binding free energy calculations, we systematically evaluated the binding mode, stability, and key residue contributions of the CMNPD10921–ASK1 complex. CMNPD10921 stably occupied the ASK1 active pocket, forming hydrophobic interactions and hydrogen bonds with multiple key amino acid residues. MM-GBSA analysis yielded a total computed binding free energy of −31.15 kcal/mol, suggesting a computationally favorable interaction, with van der Waals forces serving as the dominant energetic driver of complex stabilization. Residue energy decomposition further identified ILE324, THR288, and THR639 as major contributors to ligand binding. Integrating deep learning, molecular simulation, and quantum chemical calculations, this study successfully identified CMNPD10921 from a vast natural product library as a putative lead compound candidate targeting the ASK1 central regulatory region, offering a novel candidate molecule for anti-MASH drug development.